Lacrat

Ticagrelor, the active ingredient in Lacrat, is an antiplatelet agent presented as a tablet for oral use. It inhibits platelet aggregation to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or a prior myocardial infarction. The drug acts rapidly and provides reversible inhibition of the P2Y12 receptor, allowing for flexible management of antiplatelet therapy.

GNH USA supplies Lacrat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance.

Ticagrelor is used to inhibit platelet aggregation in the P2Y12 receptor pathway.

Acute coronary syndrome: reduces cardiovascular death, myocardial infarction and stroke in patients presenting with ACS. History of myocardial infarction: lowers the incidence of recurrent ischemic events in patients after a prior MI. Percutaneous coronary intervention: prevents thrombotic complications associated with PCI procedures.

Ticagrelor may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Dyspnea: shortness of breath often occurring early in therapy. - Minor bleeding: bruising, gum bleeding or epistaxis. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Dizziness: transient light‑headedness. - Elevated uric acid: may precipitate gout flares.

Serious or Rare Side Effects: - Severe bleeding: intracranial or gastrointestinal hemorrhage requiring medical intervention. - Thrombocytopenia: marked reduction in platelet count. - Allergic reactions: rash, angioedema or anaphylaxis. - Hepatic injury: elevated transaminases indicating liver stress. - Hypotension: sudden drop in blood pressure, especially with concomitant vasodilators.

Before prescribing Ticagrelor, clinicians should consider several safety measures.

Assess bleeding risk: evaluate patient history of hemorrhagic disorders. Avoid in active pathological bleeding: contraindicated in patients with ongoing severe bleeding. Monitor for dyspnea: discontinue if severe or worsening respiratory symptoms occur. Check hepatic function: adjust use in patients with severe liver impairment. Avoid concomitant strong CYP3A4 inhibitors: may increase drug exposure and bleeding risk. Store at ambient temperature: keep in the original container, protect from moisture and light.

Ticagrelor interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels and bleeding risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce effectiveness, risking thrombotic events. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): potentiate bleeding.

Moderate Interactions (Monitor Closely): - Aspirin and other NSAIDs: additive antiplatelet effect may raise bleeding potential. - Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin exposure; dose adjustment may be needed.